EUVIMEDEUVIMED entdecken
Multizentrische StudieOpen Access

CYP2C19 Phenotype, P2Y 12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy

Rajiv C Patel iD, Cameron D Thomas iD, Joseph S Rossi, Francesco Franchi iD, Ellen C Keeley iD, Amber L Beitelshees iD, Julio D Duarte iD, Luis Ortega-Paz, Natasha Kulick iD, Marshall Winget iD, Anh B Nguyen iD, William E Yang iD und 5 weitere

Journal of the American Heart Association · 2025

DOI: 10.1161/jaha.125.041634 ↗

Kurz gefasst

Multizentrische Studie in der Zeitschrift Journal of the American Heart Association, 2025. Verfasst von Rajiv C Patel und 16 weiteren Autor:innen. Beteiligte Einrichtung: Division of Cardiology and McAllister Heart Institute, School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA. Hauptthemen laut MEDLINE: Clopidogrel, Cytochrome P-450 CYP2C19, Purinergic P2Y Receptor Antagonists, Platelet Aggregation Inhibitors. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 33 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NHLBI NIH HHS, NHGRI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Use of CYP2C19 genotyping to guide antiplatelet therapy is associated with improved clinical outcomes in patients naïve to P2Y 12 inhibitors undergoing percutaneous coronary intervention. The relationship between CYP2C19 genotype and clinical outcomes in patients on maintenance clopidogrel at the time of percutaneous coronary intervention is unknown.

Methods

This was a retrospective, multicenter cohort study. Patients were characterized as intermediate or poor metabolizers versus normal or rapid or ultrarapid metabolizers on the basis of CYP2C19 genotype. Major adverse cardiovascular events included cardiovascular death, myocardial infarction, ischemic stroke, or stent thrombosis.

Results

The study population (N=4246) had a median age of 63.0 (interquartile range, 55.0–71.0) years, was 66.8% men, and 21.3% Black individuals. During 12‐month follow‐up, major adverse cardiovascular event rates were higher (7.4% versus 4.8%; P

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClopidogrelCytochrome P-450 CYP2C19Purinergic P2Y Receptor AntagonistsPlatelet Aggregation InhibitorsPercutaneous Coronary InterventionPharmacogenomic VariantsCoronary Artery DiseaseHumansMaleFemaleMiddle AgedRetrospective StudiesAgedPhenotypeTreatment OutcomeGenotypeRisk FactorsTicagrelorRisk AssessmentPrasugrel Hydrochloride

Stichwörter der Autor:innen

ACSMACEPCIclopidogrelgenotyping

Substanzen

ClopidogrelCytochrome P-450 CYP2C19Purinergic P2Y Receptor AntagonistsCYP2C19 protein, humanPlatelet Aggregation InhibitorsTicagrelorPrasugrel Hydrochloride

Autor:innen und Institutionen

  • Division of Cardiology and McAllister Heart Institute, School of Medicine University of North Carolina at Chapel Hill Chapel Hill NC USA.
  • Department of Pharmacotherapy & Translational Research and Center for Pharmacogenomics and Precision Medicine, College of Pharmacy University of Florida Gainesville FL USA.
  • Division of Cardiology, Department of Medicine, College of Medicine-Jacksonville University of Florida Jacksonville FL USA.
  • Division of Cardiovascular Medicine, College of Medicine University of Florida Gainesville FL USA.
  • Department of Medicine and Program for Personalized and Genomic Medicine University of Maryland School of Medicine Baltimore MD USA.
  • Division of Pharmacotherapy and Experimental Therapeutics, Eshelman School of Pharmacy University of North Carolina at Chapel Hill Chapel Hill NC USA.

ORCID-Profile: Rajiv C Patel, Cameron D Thomas, Francesco Franchi, Ellen C Keeley, Amber L Beitelshees, Julio D Duarte, Natasha Kulick, Marshall Winget, Anh B Nguyen, William E Yang, Dominick J Angiolillo, Larisa H Cavallari, Craig R Lee, George A Stouffer

Förderung

  • NHLBI NIH HHS
  • NHGRI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Patel, R. C., Thomas, C. D., Rossi, J. S., Franchi, F., Keeley, E. C., Beitelshees, A. L., Duarte, J. D., Ortega-Paz, L., Kulick, N., Winget, M., Nguyen, A. B., Yang, W. E., Venkatesh, S., Angiolillo, D. J., Cavallari, L. H., Lee, C. R., & Stouffer, G. A. (2025). CYP2C19 Phenotype, P2Y 12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy. Journal of the American Heart Association. https://doi.org/10.1161/jaha.125.041634

Vancouver

Patel RC, Thomas CD, Rossi JS, Franchi F, Keeley EC, Beitelshees AL, et al. CYP2C19 Phenotype, P2Y 12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy. Journal of the American Heart Association. 2025. doi:10.1161/jaha.125.041634

BibTeX
@article{Patel2025,
  author = {Patel, Rajiv C and Thomas, Cameron D and Rossi, Joseph S and Franchi, Francesco and Keeley, Ellen C and Beitelshees, Amber L and Duarte, Julio D and Ortega-Paz, Luis and Kulick, Natasha and Winget, Marshall and Nguyen, Anh B and Yang, William E and Venkatesh, Sanjay and Angiolillo, Dominick J and Cavallari, Larisa H and Lee, Craig R and Stouffer, George A},
  title = {CYP2C19 Phenotype, P2Y 12 Inhibitor Selection, and Clinical Outcomes in Patients on Maintenance Clopidogrel Therapy},
  journal = {Journal of the American Heart Association},
  year = {2025},
  doi = {10.1161/jaha.125.041634}
}
Kostenlos starten →